Federation of American Scientists Case Studies in Dual Use Biological Research Module 3.0: Aerosol Delivery Case Study
Topic: References

References for History of Asthma and Aerosolized Medicines
(1)
Taken from Fink, James B. and Rau, Joseph L., “New Horizons in Respiratory Care: The Pharmacology of Inhaled Aerosol Drug Therapy," Respiratory Care Journal, 45(7): 824-5 (2000).
 
(2)
American Lung Association, Epidemiology and Statistics Unit, Research and Program Services, Trends in Asthma Morbidity and Mortality, May 2005.
 
(3)
Dey, A.N., Schiller, J.S., Tai, D.A. Summary Health Statistics for U.S. Children: National Health Interview Survey, 2002. National Center for Health Statistics. Vital Health Stat 10(221): 2004-1549 (2002).
 
(4)
Centers for Disease Control and Prevention, “Surveillance for Asthma – United States, 1960-1995," Morbidity and Mortality Weekly Report, 47 (SS-1): 1-28 (1998).
 
(5)
Asthma and Allergy Foundation of America, “Information about Asthma Allergies;” available at http://www.aafa.org/display.cfm?id=8&cont=8.
 
(6)
Gandevia, B., “Historical review of the use of parasympaholytic agents in the treatment of respiratory disorders,” Postgrad Medical Journal, 51 (7 Suppl): 13-20 (1975).
 
(7)
Op. cit., Fink, et. al.
(8)
Borgstrom, L. “Local versus total systemic bioavailability as a means to compare different inhaled formulations of the same substance,” Journal of Aerosol Medicine, 11(1): 55-63 (1998).
 
(9)
Bisgaard, et. al., editor, “Drug Delivery to the Lung,” Drug Delivery Reference from Culinary and Hospitality Industry Publications Services (2001).
 
(10)
Crowder, Timothy M., et. al., “Fundamental Effects of Particle Morphology on Lung Delivery: Prediction of Stokes’ Law and the Particular Relevance to Dry Powder Inhaler Formulation and Development," Pharmaceutical Research, 19: 239-245 (2002).
 
References for Designing Porous Particles
(11)
Taken from Edwards, David, “Delivery of Biological Agents by Aerosols,” AIChE Journal, Vol. 48, No. 1, January 2002.
(12)
Heyder, J. et. al., “Deposition of Particles in the Human Respiratory Tract in the Size Range 0.005-15µm,” Journal of Aerosol Science, Vol. 17: 811 (1986).
 
(13)
Op. cit., Edwards, David.
(14)
Op. cit., Edwards, David.
(15)
Ben-Jebria, A., et. al., “Inhalation of Large Porous Albuterol Particles for Sustained Bronchodilation,” Pharm. Res., Vol. 16., 555 (1999).
(16)
Ibid.
(17)
Ibid.

Back Next
Topic History of Asthma and Aerosolized Medicines Designing Porous Particles Implications Discussion References Home